**[126] SILENSEED IS A CLINICAL STAGE (PHASE2) BIOPHARMACEUTICAL COMPANY DEVELOPING RNAI-BASED THERAPIES FOR SOLID TUMORS. THE COMPANY COMPLETED A SUCCESSFUL PHASE 1/2A STUDY IN PANCREATIC CANCER, SHOWING EARLY EVIDENCE OF TUMOR HALTING AND LIFE EXTENSION. THERAPIES ARE BASED ON PROPRIETARY DRUGS AND LODER™ DELIVERY PLATFORM; PIPELINE INCLUDES PANCREATIC, PROSTATE AND BRAIN TUMORS. COMPANY HAS ESTABLISHED IN-HOUSE CGMP MANUFACTURING AND SUCCESSFULLY COMPLETED GLP TOXICOLOGICAL STUDIES.**

**Amotz Shemi1, 1 Silenseed**

**Silenseed**

* **Investment Rational**   
  Silenseed is a clinical stage (Phase2) biopharmaceutical company developing RNAi-based therapies for solid tumors. The company completed a successful Phase 1/2a study in pancreatic cancer, showing early evidence of tumor halting and life extension. Therapies are based on proprietary drugs and LODER™ delivery platform; pipeline includes pancreatic, prostate and brain tumors. Company has established in-house cGMP manufacturing and successfully completed GLP toxicological studies
* **Business Strategy**   
  In-house development and cGMP production, out-licensing and collaborations
* **Core Technology**   
  Silenseed develops new RNAi-based drugs and the LODER (Local Drug EluteR) platform, specifically the siG12D-LODER, a miniature biodegradable polymeric matrix encompassing the new anti-KRAS siRNA drug. KRAS is a well-known dominating cancer driver that so far considered as undrugable
* **Product Profile/Pipeline**   
  siG12D-LODER for pancreatic cancer.
* Prostate-LODER for prostate-cancer;
* Nano-LODER for brain and more solid tumors
* **What's Next?**
  + Clinical Development – Phase 2 in pancreatic cancer in US, EU and Israel PIs: Eileen O’reilly, MSK, Daniel Von Hoff, MayoClinic; and more leading oncology sites
  + Organizational plans – HQ in Israel, subsidiary in US, EU, Far East
  + R&D – Next gen LODER platform and RNAi-based oncology drug
  + Financial plans – private $10m, IPO, collaborations

**Summary**

* Opportunity: Pancreatic cancer: urgent, unmet need (TAM $5.1B; Oncology: $89B)
* Technology: clinically validated, platform, large class of cancer (prostate, brain, breast..)
* Regulatory: Orphan drug (approved), 7-year marketing exclusivity
* Status: Phase 1/2a results – safe, evidence of efficacy
* IP: 6 granted patents, valid until 2029-2033

People: Strong business oriented board: Ilan Shiloah, Chairman, investor (LON:MTMY); Len Potter, President of Wildcat Capital (investor), Dr. Amotz Shemi, CEO, co-founder, (SVP Technologies Medinol, CEO, ColorChip); KOLs/investors; Prof. Michael Sela, investor (Copaxone®, Erbitux®); Prof. Ruth Arnon, investor (Copaxone®); Dr. Shmuel Cabilly, investor (“Cabilly Patents”); Prof. Eithan Galun, co-founder, (Hadassah);Dr. Ettie Pirak, investor, (Erbitux®), Prof. Abraham Domb, (Gliadel®); Prof. John Rossi, Prof. Yechezkel Barenholz, (Doxil®)